we are a nasdaq-listed special purpose acquisition company whose business purpose is to effect a merger or similar business combination with one or more businesses. our acquisition strategy is to identify and complete our initial business combination with a medical technology company in the healthcare industry. our sponsor team consists of chairman/ceo robert palmisano, president vikram malik, cfo oleg grodnensky and chief legal officer david meredith.
Company profile
Ticker
AEON, AEON-WT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Priveterra Acquisition Corp.
SEC CIK
Corporate docs
IRS number
853940478
AEON stock data
Latest filings (excl ownership)
S-1/A
IPO registration (amended)
31 May 24
8-K
Departure of Directors or Certain Officers
16 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
AEON Biopharma Reports First Quarter 2024 Financial Results
14 May 24
DEFA14A
Additional proxy soliciting materials
14 May 24
10-K/A
2023 FY
Annual report (amended)
14 May 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
3 May 24
8-K
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
3 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
Latest ownership filings
3
Jennifer Sy
24 May 24
3
Seongsoo Park
18 Apr 24
4/A
Change in insider ownership (amended)
16 Apr 24
4
Change in insider ownership
12 Apr 24
4
Change in insider ownership
26 Mar 24
4
Shelley B Thunen
21 Mar 24
4
ROBERT J PALMISANO
21 Mar 24
4
Marc Forth
21 Mar 24
4
Chad Oh
21 Mar 24
4
JOST FISCHER
21 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm |
Cash burn (monthly) | 1.20 mm | 473.75 k | 39.34 mm | 14.01 mm | 2.87 mm | 2.48 mm |
Cash used (since last report) | 2.52 mm | 995.37 k | 82.65 mm | 29.44 mm | 6.02 mm | 5.20 mm |
Cash remaining | -963.26 k | 562.63 k | -81.10 mm | -27.88 mm | -4.47 mm | -3.64 mm |
Runway (months of cash) | -0.8 | 1.2 | -2.1 | -2.0 | -1.6 | -1.5 |
Institutional ownership, Q1 2024
35.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 53 |
Opened positions | 29 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 106.59 bn |
Total shares | 13.81 mm |
Total puts | 0.00 |
Total calls | 184.56 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Polar Asset Management Partners | 3.70 mm | $42.67 bn |
Atalaya Capital Management | 3.68 mm | $36.24 bn |
Strathspey Crown | 2.03 mm | $14.26 mm |
Vanguard | 758.99 k | $8.80 bn |
Davidson Kempner Capital Management | 366.67 k | $531.67 mm |
Ikarian Capital | 257.98 k | $2.99 bn |
LMR Partners | 256.61 k | $439.15 mm |
BLK Blackrock | 255.42 k | $2.96 bn |
GS Goldman Sachs | 248.68 k | $2.08 bn |
Wolverine Asset Management | 189.15 k | $274.27 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | Daewoong | Senior Secured Convertible Note Common Stock | Other | Acquire J | Yes | No | 0 | - | 10.00 mm | - |
11 Apr 24 | Daewoong | Senior Secured Convertible Note Common Stock | Other | Acquire J | Yes | No | 0 | - | 10.00 mm | - |
24 Mar 24 | Daewoong | Senior Secured Convertible Note Common Stock | Other | Acquire J | Yes | No | 0 | - | 5.00 mm | - |
News
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $6 Price Target
30 May 24
AEON Biopharma Announces Strategic Resource Reprioritization And Cost Reduction Plan; AEON Has Reduced Its Workforce By ~55%
29 May 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
23 May 24
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $6
15 May 24
AEON Biopharma Q1 2024 Adj EPS $(3.17) Misses $(0.31) Estimate
14 May 24
Press releases
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
3 May 24
AEON Biopharma Announces Redemption of Public Warrants
29 Mar 24
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 24
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
19 Mar 24